Trial · NCT05832320
Optimum Induction Therapy of Low-risk APL
NCT05832320, Not applicable, Unknown, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Optimum Induction Therapy of Low-risk APL. Trials, record NCT05832320. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05832320
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimum Induction Therapy of Low-risk APL
- NCT number
- NCT05832320
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 74 participants, estimated
- Lead sponsor
- Peking University People's Hospital
- Conditions
- Acute Promyelocytic Leukemia, Induction Therapy, Oral
- Interventions
- Etoposide, Daunorubicin
- First posted
- 2023-04-27
- Last updated
- 2024-05-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete remission | At the end of induction therapy within 45 days after diagnosis | Haematological CR was defined as a proportion of BM blasts of \<5%, the absence of blasts in Auer rods, the absence of extramedullary disease, an absolute neutrophil count of \>1×10⁹/L and a platelet count of \>100×109/L, with no red-cell transfusions |
| Primary | Promyelocytic leukaemia-retinoic acid receptor alpha (PML-RARA) transcript levels of ≥6.5% at the end of induction therapy | At the end of induction therapy within 45 days after diagnosis | PML-RARA transcripts using Abelson tyrosine-protein kinase (ABL) as an internal control by quantitative RT-PCR |
| Secondary | Early death (ED) | During the induction therapy within 30 days after diagnosis | Defined as death within 30 days after diagnosis |
| Secondary | Cumulative recurrence rate | From date of randomization until the date of last documented progression or date of death from any cause, whichever came first, assessed up to 2 years | A measure of the total relapse that a certain event will happen during a given period of time |
| Secondary | 2-year event-free survival rate | From the time of randomization to the time of last follow-up within 2 years after diagnosis | The EFS was defined as the time from diagnosis to the following events: no haematological CR after induction therapy; no CMR after consolidation therapy, molecular relapse, haematological relapse; death from any cause; or last follow-up. |
| Secondary | Satefy. Common haematological and non-haematological adverse events were monitored twice per week during induction and twice per month during consolidation. | From the time of randomization to the time of last follow-up within 2years after diagnosis | Toxic effects were graded according to the 'WHO classification standard for acute and subacute toxicity of anticancer drugs'. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05832320
GET https://conductscience.org/api/trials/v1/NCT05832320/registered